Browse studies

Find your next paid study

85 recruiting studies matching your filters

A Phase 2b/Phase 3, Randomized, Double-blind, Placebocontrolled, Multicenter Study, to Investigate the Efficacy and Safety of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared…

Chronic Obstructive Pulmonary Disease

Estimated

~$10 – $7,500

SanofiNCT07190209

Biomarkers and Protein Mass Expression Profiles in Bronchoalveolar Lavage From Patients With Lung Infiltrates

This study will examine the different types of proteins present in the lungs of patients with pneumonia to explore the causes of different types of the disease…

PneumoniaPulmonary DiseaseLung Disease

Estimated

~$10 – $675

National Institutes of Health Clinical Center (CC)NCT00077909

Phase 4

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Mucus Plugging and Other Lung Imaging Parameters in Patients With Chronic Obstructive Pulmonary Disease.

LPS18583 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 4 study with 2 treatment groups. The purpose of this study is …

Chronic Obstructive Pulmonary Disease

An Extension Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig, Including Inhaled Corticosteroid Withdrawal, in Adults With Chronic Obstructive Pulmonary Disease (COPD) Who Completed Studies EFC18243 or EFC18244

This is an open-label, Phase 3, long-term safety extension study including participants of previous lunsekimig clinical trials with inadequately controlled chr…

Chronic Obstructive Pulmonary Disease

Estimated

~$10 – $7,500

SanofiNCT07793409

A Prospective, Multicenter, Single-arm MAC-PD Cohort: a NTM-NET and ESGMYC Collaborative Study

To gain insight in the effectiveness of, adherence and adjustments to guideline-based three-drug antimycobacterial therapy in patients with Mycobacterium avium…

Mycobacterium Avium Complex Pulmonary Disease

Estimated

~$10 – $750

Radboud University Medical CenterNCT05906316

Phase 2

A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of WIN378 in Participants With Moderate - Severe Chronic Obstructive Pulmonary Disease

This study is trying to identify the right dose of a long-acting medicine called WIN378 for people with moderate - severe chronic obstructive pulmonary disease…

COPD (Chronic Obstructive Pulmonary Disease)

Estimated

~$10 – $7,500

Windward BioNCT07646587

Phase 4

Nebulizer Versus Handheld Maintenance Therapy for Patients With COPD

Multi-site, randomized controlled trial to determine whether patients who report NO symptomatic benefit with their maintenance hand-held inhaler(s), benefit up…

COPD (Chronic Obstructive Pulmonary Disease)Chronic Obstructive Pulmonary Disease (COPD)

Estimated

~$10 – $6,250

COPD FoundationNCT07816835

Phase 2

A Multicentre, Parallel-group, Phase IIb, Randomised, Double-blind, Placebo-controlled, 3-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO)

This Phase IIb dose-ranging study will evaluate the efficacy and safety of 2 different doses of AZD6793 compared with placebo tablets in participants with mode…

Chronic Obstructive Pulmonary Disease (COPD)

Estimated

~$10 – $7,500

AstraZenecaNCT07082738

Observational

Using Community Health Workers to Support Rural Care Partners of Seriously Ill Older Veterans

The investigators aim to support care partner's well-being and satisfaction with VA care and decrease their work burden by offering extra support from a traine…

DementiaCancerRenal Disease+1 more

Estimated

~$10 – $5,625

VA Office of Research and DevelopmentNCT06963970

Phase 3

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study of the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants 40 to 80 Years of Age With Moderate to Very Severe COPD (PERSIST COPD-1)

The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and …

Pulmonary Disease, Chronic Obstructive

Estimated

~$10 – $7,500

GlaxoSmithKlineNCT07780669

Phase 2

Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD (COPD-OMA)

This research is being done to test if a drug called omalizumab can help people with Chronic Obstructive Pulmonary Disease (COPD) and allergies. Each particip…

Chronic Obstructive Pulmonary Disease (COPD)Allergies

Estimated

~$10 – $6,250

Johns Hopkins UniversityNCT07059091

Phase 3

A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Mo…

Chronic Obstructive Pulmonary Disease (COPD)

Estimated

~$10 – $7,500

AstraZenecaNCT06883305